Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 363Precursor Cell Lymphoblastic Leukemia-Lymphoma 89Leukemia 61Neoplasms, Plasma Cell 60Lymphoma 59Recurrence 52Neoplasms 34Vomiting 33Lymphoma, Non-Hodgkin 32Immunoglobulin Light-chain Amyloidosis 27Lymphoma, Mantle-Cell 26Burkitt Lymphoma 26Nausea 22Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 21Waldenstrom Macroglobulinemia 19Prostatic Neoplasms 19Lymphoma, Follicular 18Hodgkin Disease 18Neoplasm Metastasis 14Breast Neoplasms 14Amyloidosis 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Acute 11Carcinoma, Non-Small-Cell Lung 11Ovarian Neoplasms 9Lymphoma, Large-Cell, Immunoblastic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Colonic Neoplasms 8

Interventions

Paclitaxel 5Vincristine 3Oxaliplatin 3Mental Status and Dementia Tests 3Magnetic Resonance Spectroscopy 3Carboplatin 3Amifostine 3xaliproden 2glucarpidase 2Taxes 2Radiotherapy 2Psychiatric Rehabilitation 2Procarbazine 2Methotrexate 2Magnesium Sulfate 2Leucovorin 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Calcium Gluconate 22,2'-dithiodiethanesulfonic acid 2neurotropin 1glutamic acid diethyl ester 1eribulin 1axicabtagene ciloleucel 1Vitamin E 1Trastuzumab 1Thioctic Acid 1Thalidomide 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neurotoxicity Syndromes × Dexamethasone × Clear all
NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
45 enrolled 8 charts
Plasma cell

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡